CD274 and ovarian carcinoma: In the realm of ovarian cancer treatment, a compelling avenue for enhancing the efficacy of NK cell-based immunotherapy lies in the integration of immune checkpoint inhibitors (ICIs) and PD-L1 blockade (74).